Zanubrutinib (Brukinsa®). HTA ID: 21044

Assessment Status Rapid review complete
HTA ID 21044
Drug Zanubrutinib
Brand Brukinsa®
Indication Monotherapy for the treatment of adult patients with Waldenström’s macroglobulinaemia who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy
Assessment Process
Rapid review commissioned 11/10/2021
Rapid review completed 16/11/2021
Rapid review outcome A full HTA is not recommended. The NCPE recommends that zanubrutinib (Brukinsa®) not be considered for reimbursement at the submitted price*

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013

The HSE has approved reimbursement following confidential price negotiations May 2022.